Literature DB >> 35505031

Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy.

Marion M Deken1, Shadhvi S Bhairosingh1, Alexander L Vahrmeijer1, Sabrina Oliveira2,3.   

Abstract

Photodynamic therapy (PDT) is characterized by the local application of laser light, which activates a photosensitizer to lead to the formation of singlet oxygen and other toxic reactive oxygen species, to finally kill cells. Recently, photosensitizers have been conjugated to nanobodies to render PDT more selective to cancer cells. Nanobodies are the smallest naturally derived antibody fragments from heavy-chain antibodies that exist in animals of the Camelidae family. Indeed, we have shown that nanobody-targeted PDT can lead to extensive and selective tumor damage, and thus the subsequent step is to assess whether this damage can delay or even inhibit tumor growth in vivo. To evaluate the therapeutic efficacy of PDT, mouse models are mostly employed in which human tumors are grown subcutaneously in the flank of the animals. Although very useful, it has been suggested that these tumors are further away from their natural environment and that tumors developed in the organ or tissue of origin would be closer to the natural situation. Thus, this chapter describes the development of an orthotopic model of breast cancer and the application of nanobody-targeted PDT, for the assessment of the therapeutic efficacy.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Nanobody-photosensitizer; Orthotopic breast cancer model; Targeted photodynamic therapy

Mesh:

Substances:

Year:  2022        PMID: 35505031     DOI: 10.1007/978-1-0716-2099-1_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.

Authors:  Barbara Korsak; Gabriela M Almeida; Sara Rocha; Carla Pereira; Nuno Mendes; Hugo Osório; Patrícia M R Pereira; João M M Rodrigues; Rudolf J Schneider; Bruno Sarmento; João P C Tomé; Carla Oliveira
Journal:  Int J Cancer       Date:  2017-07-10       Impact factor: 7.396

2.  Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.

Authors:  Kimihiro Ito; Makoto Mitsunaga; Takashi Nishimura; Masayuki Saruta; Takeo Iwamoto; Hisataka Kobayashi; Hisao Tajiri
Journal:  Bioconjug Chem       Date:  2017-04-26       Impact factor: 4.774

3.  Nanobody-photosensitizer conjugates for targeted photodynamic therapy.

Authors:  Raimond Heukers; Paul M P van Bergen en Henegouwen; Sabrina Oliveira
Journal:  Nanomedicine       Date:  2014-01-03       Impact factor: 5.307

Review 4.  Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Authors:  James E Talmadge; Rakesh K Singh; Isaiah J Fidler; Avraham Raz
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

5.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

6.  Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: preclinical experience.

Authors:  Kazuhide Sato; Tadanobu Nagaya; Peter L Choyke; Hisataka Kobayashi
Journal:  Theranostics       Date:  2015-03-19       Impact factor: 11.556

7.  Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.

Authors:  Timo W M De Groof; Vida Mashayekhi; Tian Shu Fan; Nick D Bergkamp; Javier Sastre Toraño; Jeffrey R van Senten; Raimond Heukers; Martine J Smit; Sabrina Oliveira
Journal:  Mol Pharm       Date:  2019-06-19       Impact factor: 4.939

8.  EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.

Authors:  Pieter B A A van Driel; Martin C Boonstra; Maxime D Slooter; Raimond Heukers; Marieke A Stammes; Thomas J A Snoeks; Henriette S de Bruijn; Paul J van Diest; Alexander L Vahrmeijer; Paul M P van Bergen En Henegouwen; Cornelis J H van de Velde; Clemens W G M Löwik; Dominic J Robinson; Sabrina Oliveira
Journal:  J Control Release       Date:  2016-03-15       Impact factor: 9.776

9.  Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging.

Authors:  Henriette S de Bruijn; Vida Mashayekhi; Tom J L Schreurs; Pieter B A A van Driel; Gustav J Strijkers; Paul J van Diest; Clemens W G M Lowik; Ann L B Seynhaeve; Timo L M Ten Hagen; Jeanine J Prompers; Paul M P van Bergen En Henegouwen; Dominic J Robinson; Sabrina Oliveira
Journal:  Theranostics       Date:  2020-01-20       Impact factor: 11.556

10.  Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.

Authors:  Marion M Deken; Marta M Kijanka; Irati Beltrán Hernández; Maxime D Slooter; Henriette S de Bruijn; Paul J van Diest; Paul M P van Bergen En Henegouwen; Clemens W G M Lowik; Dominic J Robinson; Alexander L Vahrmeijer; Sabrina Oliveira
Journal:  J Control Release       Date:  2020-04-21       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.